Regenicin (Regenicin) Change In Receivables : $0.00 Mil (TTM As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Regenicin Change In Receivables?

Regenicin's change in receivables for the quarter that ended in Mar. 2023 was $0.00 Mil. It means Regenicin's Accounts Receivable stayed the same from Dec. 2022 to Mar. 2023 .

Regenicin's change in receivables for the fiscal year that ended in Sep. 2022 was $0.00 Mil. It means Regenicin's Accounts Receivable stayed the same from Sep. 2021 to Sep. 2022 .

Regenicin's Accounts Receivable for the quarter that ended in Mar. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Regenicin's liquidation value for the three months ended in Mar. 2023 was $-6.21 Mil.

Regenicin Change In Receivables Historical Data

The historical data trend for Regenicin's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Change In Receivables Chart

Regenicin Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Change In Receivables

Get a 7-Day Free Trial

Regenicin Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Regenicin Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Regenicin (OTCPK:RGIN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Regenicin's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Regenicin's accounts receivable are only considered to be worth 75% of book value:

Regenicin's liquidation value for the quarter that ended in Mar. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	11.859	-	18.07	+	0.75 * 0	+	0.5 * 0
=	-6.21

Regenicin Change In Receivables Related Terms

Thank you for viewing the detailed overview of Regenicin's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenicin (Regenicin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 High Court, Little Falls, NJ, USA, 07424

Website

https://www.regenicin.com

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines